[PDF] Top 20 <p>Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study</p>
Has 10000 "<p>Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study</p>" found on our website. Below are the top 20 most common "<p>Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study</p>".
<p>Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study</p>
... of patients without inadequate analgesia. Patients were assessed to have inadequate analgesia with S-8117 during the maintenance period if they met one of the following criteria: (i) wor- sened pain ... See full document
14
<p>Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study</p>
... Unlike Western countries, Japan has a low incidence of drug abuse, including that of opioids, and thus, no standard assessment procedures are established yet. In the current study, withdrawal syndrome was assessed ... See full document
13
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
... varies from patient to patient and results from three random- ized controlled trials have shown that the BFI is a val- idated, easy-to-use questionnaire for the measurement of opioid induced ... See full document
11
Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
... the efficacy was maintained for such an extended ...our study, we found no loss of analgesia and only a moderate increase of the daily dose over time (from 10 mg of oxycodone to ...the ... See full document
9
A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain
... of chronic illness (one stage IV non-small-cell lung cancer, one atherosclerotic coronary artery ...the study drug. A fifth subject died 13 months after the study by suicide due to ... See full document
10
Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
... multicenter, open-labeled, randomized, parallel-group, active-control study ...old; moderate to severe cancer- related pain ...(NRS) pain score ≥4] that required ... See full document
9
Original Article Efficacy and safety of titration with controlled-release oxycodone versus immediate-release morphine in patients with moderate cancer pain
... CR oxycodone formula- tions have been applied for pain titration in cancer patients, and have ideal ...of cancer pain intensity in target ...current study, the time to ... See full document
8
Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature
... both chronic cancer and noncancer pain, and their ability to be placed into controlled release (CR) formulations suggests that they may prove efficacious for OA ...formulation, ... See full document
11
Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
... IR oxycodone entered the Open-label Titration ...to Oxycodone DETERx (n=22) or pla- cebo (n=22) in the 12-week Double-blind Maintenance ...Phase. Efficacy results in this ... See full document
9
A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide
... This open-label, single-arm study was conducted in 157 primary care centers in the United ...with chronic moderate-to-severe pain were converted to oral administration of ... See full document
14
<p>Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients</p>
... pediatric patients led to the establishment of regulatory frameworks for the develop- ment of pediatric medications by both the European Medicines Agency and the Food and Drug ...rst pain medication to ... See full document
14
Alitretinoin for the treatment of severe chronic hand eczema
... its management, systemic treatment is necessary in a number of ...in patients who fail potent topical cor- ...for patients to receive, due to a necessity to travel to ...the patients treated ... See full document
6
<p>The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain</p>
... between pain severity and economic burden, with the highest costs incurred by patients with severe ...high pain severity was associated with a heavier burden of comorbidities, increased use of ... See full document
8
<p>Tapentadol for neuropathic pain: a review of clinical studies</p>
... (PD) pain is one of the most frequent non-motor symptoms throughout the disease course, sometimes preceding the clinical motor stage for ...PD patients present prevalent nociceptive muscu- loskeletal ... See full document
15
Buprenorphine and pain treatment in pediatric patients: an update
... In a 1989 study, BPN was administered intravenously at a premedication dose of 3 m g/kg among patients undergo- ing minor surgery (4.6–7.5 years). The PK showed a bi- exponential behavior (due to ... See full document
11
Teneligliptin in management of type 2 diabetes mellitus
... The efficacy and safety of teneligliptin in diabetic ESRD patients undergoing hemodialysis were studied through a bicenter, prospective, nonrandomized ...45 patients were enrolled in this ... See full document
10
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
... 1. Patients were also excluded for the use of long-term oxygen therapy (prescribed for ...than study medication, with the exception of inhaled corticosteroids ...excluded patients from the ... See full document
12
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
... Brodalumab, a human antiinterleukin-17 receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase 2 random[r] ... See full document
11
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
... single-arm, open-label, long-term Japanese ...91 patients were enrolled, including 78 affected by moderate-to-severe plaque psoriasis, eight by erythrodermic psoriasis, and five ... See full document
9
Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature
... with moderate to severe psoriasis constitute about 30% of the psoriasis ...These patients are determined by a score greater than 10 on several indices including: total body surface area (TbSA ... See full document
10
Related subjects